Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Remdesivir  COVID-19 treatment studies for Remdesivir  C19 studies: Remdesivir  Remdesivir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality 12% Improvement Relative Risk Mortality (b) 24% Mozaffari et al. Remdesivir for COVID-19 LATE Is late treatment with remdesivir beneficial for COVID-19? Retrospective 57,710 patients in the USA Lower mortality with remdesivir (p=0.0032) Mozaffari et al., Clinical Infectious Diseases, doi:10.1093/cid/ciab875 Favors remdesivir Favors control
Remdesivir treatment in hospitalized patients with COVID-19: a comparative analysis of in-hospital all-cause mortality in a large multi-center observational cohort
Mozaffari et al., Clinical Infectious Diseases, doi:10.1093/cid/ciab875
Mozaffari et al., Remdesivir treatment in hospitalized patients with COVID-19: a comparative analysis of in-hospital all-cause.., Clinical Infectious Diseases, doi:10.1093/cid/ciab875
Oct 2021   Source   PDF  
  All Studies   Meta
Retrospective 28,855 remdesivir patients with PSM matched controls, showing lower mortality with treatment.
[Gérard, Wu, Zhou] show significantly increased risk of acute kidney injury with remdesivir.
risk of death, 12.0% lower, HR 0.88, p = 0.003, treatment 4,441 of 28,855 (15.4%), control 5,499 of 28,855 (19.1%), NNT 27, adjusted per study, 28 days, PSM, Cox proportional hazards.
risk of death, 24.0% lower, HR 0.76, p < 0.001, treatment 3,057 of 28,855 (10.6%), control 4,437 of 28,855 (15.4%), NNT 21, adjusted per study, 14 days, PSM, Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Mozaffari et al., 1 Oct 2021, retrospective, USA, peer-reviewed, 12 authors.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperRemdesivirAll
Abstract: Remdesivir treatment in hospitalized patients with COVID-19: a comparative analysis of inhospital all-cause mortality in a large multi-center observational cohort Essy Mozaffari1, Aastha Chandak2, Zhiji Zhang2, Shuting Liang1, Mark Thrun1, Robert L Gottlieb3, Haubrich1 1 Gilead Sciences, 333 Lakeside Drive, Foster City, CA, USA 94404; 2 Certara, 295 Madison Ave, 23rd Fl, New York, NY, USA 10017; 3Baylor University Medical Center Dallas; Baylor Scott and White Heart and Vascular Hospital; Baylor Scott and White The Heart Hospital Plano, and Baylor Scott and White Research Institute, 3410 Worth St, Suite 250, Dallas TX, USA 75246; 4Division of Infectious Diseases, Brigham and Women’s Hospital, Harvard Medical School, 65 Landsdowne St, Cambridge, MA, USA 02139; 5Division of Infectious Diseases, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA, USA 02115; 6University of North Carolina, 130 Mason Farm Road, Chapel Hill, NC, USA 27599 Corresponding author details: Robert L Gottlieb, MD, PhD Advanced Heart Failure and Transplant Cardiologist Baylor University Medical Center & Baylor Scott and White Research Institute 3410 Worth St, Suite 250, Dallas, TX, 75246 United States Email: © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons AttributionNonCommercial-NoDerivs licence (, which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact Daniel R. Kuritzkes4, Paul E. Sax5, David A. Wohl6, Roman Casciano2, Paul Hodgkins1, Richard Summary: Patients treated with remdesivir had a significantly lower risk of mortality compared to those not treated with remdesivir. Consistent with other studies, this large study of U.S. clinical practice supports remdesivir as a treatment option for appropriate COVID-19 patients. 2 Abstract: Background: Remdesivir (RDV) improved clinical outcomes among hospitalized COVID-19 patients in randomized trials, but data from clinical practice are limited. Nov 2020 and treated with RDV within two-days of hospitalization vs. those not receiving RDV during their hospitalization using the Premier Healthcare Database. Preferential within-hospital propensity score matching with replacement was used. Additionally, patients were also matched on baseline oxygenation level (no supplemental oxygen charges (NSO), low-flow oxygen (LFO), high-flow oxygen/non-invasive ventilation (HFO/NIV) and invasive mechanical ventilation/ECMO (IMV/ECMO) and two-month admission window and excluded if discharged within 3-days of admission (to exclude anticipated discharges/transfers within 72-hrs consistent with ACTT-1 study). Cox Proportional Hazards models were used to assess time to 14-/28-day mortality overall and for patients on NSO, LFO, HFO/NIV and IMV/ECMO. Results: 28,855 RDV patients were matched to 16,687 unique non-RDV patients. Overall, 10.6% and 15.4% RDV patients..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop